Novartis AG has been in the limelight for various reasons, reaching a 52-week high and demonstrating positive relative pricing strength. The FDA approval of
Rhapsido and a pricing shift for
Cosentyx boosted the stock by 6.1%. However, Goldman Sachs downgraded the stock status to 'Sell,' citing overvaluation. Despite this, the approval of a pill to treat stubborn skin flare-ups excited investors. The incredible performance of
Entresto and
Kisqali further propelled the stock. The company’s acquisition of
Regulus Therapeutics and a $5.7B licensing arrangement with Monte Rosa increased the stock's attractiveness. Novartis’ sales slipped, and a riskier move affected its dividend stocks. Despite a second-quarter earnings improvement, financial analysts’ rating on the stock remained cautious. The company’s collaboration with
Tempus AI was another noteworthy development. Despite bearish moves and threats of tariffs, the stock remained steady. After acquiring
Tourmaline Bio for $1.4 billion, speculation regarding the valuation surfaced. However, Novartis remained a strong momentum stock due to a solid Q2 performance, a generous stock buyback program, and its ability to attract analyst upgrades.
Novartis Stocks News Analytics from Sat, 22 Feb 2025 08:00:00 GMT to Sat, 04 Oct 2025 14:04:35 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -5
